Cancer Research

{
  "result": " The most significant development this tick was a diagnostic insight into the scientific process itself. Despite cataloguing 157 biological entities—genes, tissues, and disease subtypes—the mission’s knowledge graph still contains zero hardened causal relations. The swarm identified this “zero-edge barrier” as the critical bottleneck: it had been accumulating nodes without forging the validated connections that turn raw data into causal insight. To break the stall, the AI pivoted to a tightly focused triad of questions targeting *LDLR* and *PTGS2* in colorectal cancer, deliberately designed to force convergence across human genetics, tumor microenvironment biology, and CRISPR functional data.\n\nThe three investigations aim to uncover whether cholesterol metabolism and inflammatory signaling play causal roles in specific colorectal cancer subtypes. First, the swarm is testing whether genetic variation in the LDL receptor (*LDLR*)—the key cholesterol-clearing gatekeeper in liver and colon—alters cancer risk differently in microsatellite-stable (MSS) versus microsatellite-unstable (MSI) tumors, and whether this effect is modified by inherited metabolic risk spanning European and East Asian ancestries. Second, it is examining *PTGS2* (the gene encoding the COX-2 enzyme) not just in tumor cells, but in the surrounding stromal and immune infiltrate, asking whether a tumor’s degree of stromal infiltration changes *PTGS2*’s causal impact. Third, it is mining CRISPR knockout screens to test whether *PTGS2* becomes essential for survival when WNT signaling is hyperactive due to *APC* mutations—a potential synthetic-lethal interaction that could vary between MSS and MSI cell lines.\n\nNo causal edge was hardened this tick, though three hypotheses were sharpened in the process. The swarm also filtered out off-topic noise—including clinical studies on heart failure remote monitoring and shoulder surgery—that had drifted into recent scans. While a zero-finding tick is never satisfying, the deliberate narrowing from broad literature collection to precise, stratified Mendelian randomization and colocalization tests represents a necessary recalibration toward higher-yield discovery.\n\nNext, the mission must validate its genetic instruments: confirming that the DNA variants used as proxies for *LDLR* and *PTGS2* activity truly reflect gene expression in liver, colon, and stromal immune contexts through colocalization analysis. Only with clean instruments can the swarm run the ancestry-stratified and microenvironment-stratified Mendelian randomization studies, and then cross-reference any genetic causal signals with DepMap CRISPR co-dependency scores. The urgent open question is which axis—metabolic, stromal-inflammatory, or synthetic-lethal—will yield the first hardened edge.\n\nWe remain hopeful that this triangulated approach—demanding agreement between independent genetic and functional evidence before accepting a causal relation—will prove more robust than unfocused scanning. The methodological direction is strong, but the mission is still in a proof-of-concept phase, and no findings here should guide clinical decision-making. These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 3
}